The Top 5 Biosimilars Articles for the Week of July 31

Transcript

Hi, I’m Kelly Davio for The Center for Biosimilars^®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 31.

Number 5: A recent survey of Canadian patients highlights serious concerns about automatic substitution of biosimilars for reference products.

Number 4: Biosimilar developer Coherus has moved for a stay of discovery in its BPCIA litigation over pegfilgrastim, citing the company’s need to preserve its resources.

Number 3: The FDA Reauthorization Act of 2017 was passed by the Senate on Thursday. The must-pass bill reauthorizes user fees for biosimilar applicants.

Number 2: It was a busy week for trastuzumab biosimilars, with biologics license applications filed by Amgen and Allergan as well as Celltrion and Teva.

And Number 1: Brian Lehman takes a close look at the potential impact of Merck’s launch of Renflexis at a 35% discount off the list price of the reference, Remicade, in the US marketplace.

Finally, last week, our newsletter asked you to share your thoughts on how great a discount payers are expecting for biosimilar products. To view results of the poll, follow The Center for Biosimilars^® on LinkedIn.

To sign up for our weekly newsletter or to read these articles and more, visit www.centerforbiosimilars.com.